11 analysts have expressed a variety of opinions on Glaukos GKOS over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 3 | 0 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 1 | 0 | 1 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $156.45, a high estimate of $185.00, and a low estimate of $120.00. Witnessing a positive shift, the current average has risen by 10.26% from the previous average price target of $141.89.
Exploring Analyst Ratings: An In-Depth Overview
A comprehensive examination of how financial experts perceive Glaukos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Thomas Stephan | Stifel | Raises | Buy | $175.00 | $153.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $185.00 | $152.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $153.00 | $145.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $162.00 | $132.00 |
| Danielle Antalffy | UBS | Announces | Buy | $182.00 | - |
| Thomas Stephan | Stifel | Raises | Buy | $153.00 | $145.00 |
| Patrick Wood | Morgan Stanley | Announces | Underweight | $120.00 | - |
| Ryan Zimmerman | BTIG | Raises | Buy | $149.00 | $140.00 |
| Allen Gong | JP Morgan | Raises | Overweight | $145.00 | $130.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $145.00 | $135.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $152.00 | $145.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Glaukos compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Glaukos's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Glaukos analyst ratings.
All You Need to Know About Glaukos
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Glaukos: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.86%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -22.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.21%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.32%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
